A case of peeling skin syndrome type 1 with novel CDSN gene variation successfully treated with upadacitinib
- 8 October 2024
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (3) , 526-530
Abstract
Peeling skin syndrome type 1 (PSS1) is an autosomal recessive genodermatosis caused by the CDSN gene loss‐of‐function mutation and characterized by widespread superficial skin peeling and erythroderma with unbearable pruritus. Because of its ultra‐rarity and unclear mechanism, this rare disease has no established treatment regimen. Herein, we reported a Chinese woman who presented with congenital generalized pruritic erythroderma and exfoliation, notable for significantly elevated IgE levels. The whole exome sequencing identified an unpublished homozygous variant (c.295C>T, p.Gln99*) in the CDSN gene, confirming the diagnosis of PSS1. Immunohistochemistry analysis of the affected skin confirmed the lack of corneodesmosin expression, revealed the overexpression of T helper 2 (Th2)–related cytokines harboring interleukin (IL) 4 and IL‐13. After Janus kinase 1 (JAK1) inhibitor upadacitinib administration, both the patient's skin rashes and itching symptoms were significantly alleviated. Our work expanded the PSS1‐related CDSN gene mutation spectrums, substantiated the hypothesis regarding the overexpression of Th2‐related cytokines, and uncovered the important role of JAK1 underlying PSS1. JAK1 signaling may dominate the pathogenesis in PSS1 and represent a potential therapeutic target.Keywords
Funding Information
- National Natural Science Foundation of China
This publication has 14 references indexed in Scilit:
- Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trialsThe Lancet, 2022
- Peeling Skin Syndrome Type 1: Dupilumab Reduces IgE, But Not Skin AnomaliesJournal of Clinical Immunology, 2022
- Successful treatment of Netherton syndrome with dupilumab: A case report and review of the literatureThe Journal of Dermatology, 2021
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic DermatitisJAMA Dermatology, 2021
- Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammationAllergy, 2019
- Atopic dermatitis is associated with reduced corneodesmosin expression: role of cytokine modulation and effects on viral penetrationBritish Journal of Dermatology, 2016
- Aberrant distribution patterns of corneodesmosomal components of tape-stripped corneocytes in atopic dermatitis and related skin conditions (ichthyosis vulgaris, Netherton syndrome and peeling skin syndrome type B)Journal of Dermatological Science, 2013
- Identification of the first nonsenseCDSNmutation with expression of a truncated protein causing peeling skin syndrome type BBritish Journal of Dermatology, 2013
- Inflammatory Peeling Skin Syndrome Caused by a Mutation in CDSN Encoding CorneodesmosinJournal of Investigative Dermatology, 2011
- Loss of Corneodesmosin Leads to Severe Skin Barrier Defect, Pruritus, and Atopy: Unraveling the Peeling Skin DiseaseThe American Journal of Human Genetics, 2010